VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 15, 2008) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today preclinical data which demonstrates that the Company’s drug AL-108 reduces the physical brain damage associated with the pathological hallmarks of Alzheimer’s disease (AD) and improves the behavioural capacity to learn and retain memory.
